Cited 19 times in
Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성진실 | - |
dc.contributor.author | 조재호 | - |
dc.date.accessioned | 2016-02-19T10:58:39Z | - |
dc.date.available | 2016-02-19T10:58:39Z | - |
dc.date.issued | 2001 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/142118 | - |
dc.description.abstract | PURPOSE: The use of oral chemotherapeutic agents in chemoradiotherapy provides several advantages. Doxifluridine, an oral 5-FU prodrug, has been shown to be effective in colorectal cancer. We attempted a Phase II trial of preoperative chemoradiotherapy with doxifluridine plus a low-dose oral leucovorin in unresectable primary rectal cancer patients. In this study, toxicity and efficacy were evaluated. METHODS AND MATERIALS: There were 23 patients with primary unresectable rectal cancer in this trial, 21 of whom were available for analysis. The patients were treated with oral doxifluridine (900 mg/day) plus oral leucovorin (30 mg/day) from days 1 to 35, and pelvic radiation of 45 Gy over 5 weeks. Surgical resection was performed 5-6 weeks after the treatment. RESULTS: Acute toxicity involved thrombocytopenia, nausea/vomiting, diarrhea, and skin reaction. All were in Grade 1/2, except diarrhea, which was not only the most frequent (7 patients, 33.3%), but also the only toxicity of Grade 3 (2 patients). The clinical tumor response was shown in 5 patients (23.8%) as a complete response and 13 patients (61.9%) as a partial response. A complete resection with negative resection margin was done in 18 patients (85.7%), in 2 of whom a pathologic complete response was shown (9.5%). The overall downstaging rate in the T- and N-stage groupings was 71.4% (15 patients). CONCLUSION: This study demonstrated the efficacy and low toxicity of chemoradiotherapy with doxifluridine. Currently, a Phase III randomized trial of chemoradiotherapy is ongoing at our institute to compare the therapeutic efficacy of oral 5-FU with respect to i.v. 5-FU in locally advanced and unresectable rectal cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 435~439 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/radiotherapy* | - |
dc.subject.MESH | Adenocarcinoma/surgery | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Diarrhea/chemically induced | - |
dc.subject.MESH | Diarrhea/etiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Floxuridine/administration & dosage | - |
dc.subject.MESH | Floxuridine/adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Leucovorin/adverse effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Preoperative Care | - |
dc.subject.MESH | Radiotherapy/adverse effects | - |
dc.subject.MESH | Rectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Rectal Neoplasms/radiotherapy* | - |
dc.subject.MESH | Rectal Neoplasms/surgery | - |
dc.subject.MESH | Thrombocytopenia/chemically induced | - |
dc.subject.MESH | Thrombocytopenia/etiology | - |
dc.title | Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Jae Ho Cho | - |
dc.contributor.googleauthor | Nam Kyu Kim | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Chang Ok Suh | - |
dc.identifier.doi | 10.1016/S0360-3016(00)01585-6 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03901 | - |
dc.contributor.localId | A01956 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 11380231 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0360301600015856?np=y | - |
dc.subject.keyword | Doxifluridine | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Unresectable rectal cancer | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Cho, Jae Ho | - |
dc.contributor.affiliatedAuthor | Cho, Jae Ho | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 435 | - |
dc.citation.endPage | 439 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.50(2) : 435-439, 2001 | - |
dc.identifier.rimsid | 31616 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.